BioXcel Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTAI research report →
About the company
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation.
- CEO
- Vimal D. Mehta
- IPO
- 2018
- Employees
- 37
- HQ
- New Haven, CT, US
Price Chart
- Market Cap
- $42.61M
- P/E
- -0.21
- P/S
- 62.66
- P/B
- -0.16
- EV/EBITDA
- -2.17
- Div Yield
- 0.00%
- Gross Margin
- 27.79%
- Op Margin
- -7395.00%
- Net Margin
- -11078.53%
- ROE
- 75.79%
- ROIC
- -3439.53%
- Revenue
- $642.00K · -71.67%
- Net Income
- $-69,897,000 · -17.28%
- EPS
- $-5.73 · 75.63%
- Op Income
- $-50,267,000
- FCF YoY
- 20.01%
- 52W High
- $8.08
- 52W Low
- $1.01
- 50D MA
- $1.20
- 200D MA
- $1.69
- Beta
- 0.32
- Avg Volume
- 750.75K
Get TickerSpark's AI analysis on BTAI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Rodriguez Javier | other | 35 |
| Jun 15, 26 | Rodriguez Javier | other | 35 |
| Jun 15, 26 | Steinhart Richard I | other | 35 |
| Jun 15, 26 | Steinhart Richard I | other | 35 |
| Jun 15, 26 | Yocca Frank | other | 35 |
| Jun 15, 26 | Yocca Frank | other | 35 |
| Jun 15, 26 | Mehta Vimal | other | 219 |
| Jun 15, 26 | Mehta Vimal | other | 219 |
| May 4, 26 | Yocca Frank | other | 17,500 |
| May 4, 26 | Yocca Frank | other | 17,500 |
Our BTAI coverage
Recent articles, reports, and earnings notes.
No research on BTAI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BTAI report →Similar companies
Peers in the same neighborhood.